Femasys (FEMY) Expected to Release Quarterly Earnings on Tuesday

Femasys (NASDAQ:FEMY) is expected to be issuing its Q3 2026 resultson Tuesday, November 17th. Analysts expect Femasys to post earnings of ($0.6050) per share and revenue of $0.62 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings data on Friday, August 14th. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). Femasys had a negative net margin of 534.36% and a negative return on equity of 225.97%. The firm had revenue of $0.33 million during the quarter, compared to analyst estimates of $0.73 million.

Femasys Trading Up 3.6%

Shares of NASDAQ:FEMY opened at $1.42 on Tuesday. Femasys has a 52-week low of $1.25 and a 52-week high of $22.20. The stock has a market cap of $11.90 million, a price-to-earnings ratio of -0.40 and a beta of -2.13. The company has a quick ratio of 0.55, a current ratio of 2.14 and a debt-to-equity ratio of 0.89. The business has a 50-day moving average price of $2.10 and a 200-day moving average price of $5.84.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Wall Street Zen lowered shares of Femasys from a “sell” rating to a “strong sell” rating in a research report on Sunday. Maxim Group lowered their price target on shares of Femasys to $10.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Lake Street Capital cut their price target on Femasys to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, August 18th. Finally, Weiss Ratings lowered Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Femasys currently has an average rating of “Moderate Buy” and a consensus target price of $50.00.

About Femasys

Femasys Inc is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures.

Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.